Thursday, September 01, 2016
Interactive Map: (U.S.) AHRQ comparing healthcare stats quality etc
NHQR/DRnet - Select State
This newly integrated website provides a unified Web tool for investigating information presented in the National Healthcare Quality and Disparities Reports. It allows users to drill down from the broadest picture of healthcare quality and disparities on the national and state levels
Principles of Treatment for Borderline, Micropapillary Serous, and Low-Grade Ovarian Cancer
abstract
Borderline ovarian tumors (BOTs) are less common than epithelial ovarian cancers (EOCs). Low-grade EOCs (LG-EOCs) occur even less frequently than BOTs. After primary therapy, recurrence rates of BOTs and LG-EOCs are significantly lower and the stage-adjusted survival is higher than for high-grade EOCs. Thus, determining the best management in terms of traditional ovarian cancer staging and debulking procedures is more challenging and has been recently brought to question. This article reviews the particulars of BOTs and LG-EOCs, their similarities and differences, and how they are best managed and treated, and emphasizes the major role of surgery and the controversial role of chemotherapy. Because these tumors disproportionately affect younger women, this review addresses ovarian preservation in circumstances when fertility or hormonal preservation is desired.
(less common histopathologies) Ovarian Cancer, V1.2016, NCCN Clinical Practice Guidelines
Ovarian Cancer
Abstract
This selection from the NCCN Guidelines
for Ovarian Cancer focuses on the less common ovarian histopathologies
(LCOHs), because
new algorithms were added for LCOHs and current
algorithms were revised for the 2016 update. The new LCOHs algorithms
include
clear cell carcinomas, mucinous carcinomas, and
grade 1 (low-grade) serous carcinomas/endometrioid epithelial
carcinomas.
The LCOHs also include carcinosarcomas (malignant
mixed Müllerian tumors of the ovary), borderline epithelial tumors (also
known as low malignant potential tumors), malignant sex cord-stromal tumors, and malignant germ cell tumors.
Footnotes
Please Note
The NCCN Clinical Practice
Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus
of the authors regarding
their views of currently accepted approaches
to treatment. Any clinician seeking to apply or consult the NCCN
Guidelines®
is expected to use independent medical
judgment in the context of individual clinical circumstances to
determine any patient's
care or treatment. The National Comprehensive
Cancer Network® (NCCN®) makes no representation or warranties of any
kind regarding
their content, use, or application and
disclaims any responsibility for their applications or use in any way. The full NCCN Guidelines for Ovarian Cancer are not printed in this issue of JNCCN but can be accessed online at NCCN.org.
Subscribe to:
Posts
(
Atom
)